Alzamend Neuro (ALZN) Operating Expenses (2020 - 2026)

Alzamend Neuro has disclosed Operating Expenses across 7 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 152.07% year-over-year to $2.9 million; the TTM figure through Apr 2026 stood at $8.8 million (up 94.96% YoY), while the FY2026 annual figure was $8.8 million, up 94.96% from the prior year.
• Operating Expenses came in at $2.9 million for Q2 2026 at Alzamend Neuro, up from $2.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $5.4 million in Q1 2023 to a low of $850064.0 in Q2 2024.
• Average Operating Expenses over 5 years is $2.5 million, with a median of $2.7 million recorded in 2024.
• Year-over-year, Operating Expenses jumped 217.45% in 2022 and plunged 74.28% in 2024.
• Over 5 years, Operating Expenses stood at $3.1 million in 2022, then decreased by 6.59% to $2.9 million in 2023, then plunged by 53.2% to $1.4 million in 2024, then fell by 26.51% to $998109.0 in 2025, then jumped by 187.63% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $2.9 million in Q2 2026, $2.2 million in Q1 2026, and $998109.0 in Q4 2025.